|12:00 – 13:45||Registration And Networking Refreshments|
|13:45 – 14:05||Welcome and opening remarks Lisa Anson,
President, AstraZeneca UK & President, The Association of the British Pharmaceutical Industry (ABPI)
|14:05 – 14:35||Interview with Dr Ian Hudson
Chief Executive, Medicines and Healthcare Products Regulatory Agency (MHRA)
|14:35 – 15:35||Plenary Discussion One:
A New Value Proposition for Pharma
|15:35 – 16:05||Networking Refreshment Break|
|16:05 – 17:05||Plenary Discussion Two:
Disruption for Afar: Embracing New Non-Pharma Technologies & Actors
|17:05 – 17:35||Interview with Dr Franz Humer
Former Chairman, Roche & Diageo
|17:35 – 19:15||Networking Drinks Reception|
How to source and finance innovation
How to improve access
How to improve efficiency and effectiveness of pharma R&D
How to engage physicians and patients
How to improve efficiency and effectiveness of the supply chain
|Timings||Track 1||Track 2||Track 3|
|08:30-08:55||Coffee & Pastries|
|9:00-10:00||The Live, Thrive and Survive Guide to M&A||Patient Centricity I: Patient input to Improve Patient Outcomes||The New Pharma Supply Chain|
|10:05-11:05||Pricing, Affordability and an Increased Push for Transparency||Rethinking Pharma Productivity||Outsourcing Strategies:
The Evolving role of CDMOs
|11:05-11:35||Networking Refreshment Break|
|11:35-12:35||Financing the Future and Paying for Innovation||The Future of Pharma Biotech||The Future of Pharmaceutical Manufacturing and Supply Chains|
|13:35-14:35||Speed to Access:
Adaptive & Accelerated R & D
|Patient Centricity II: The Patient Data Revolution Continues||Delivering the Undeliverable|
|14:40-15:40||The Data Debate:
Integrity and Access
|De-risking Pharma|| Serialisation:
The Clock is Ticking
|15:40-16:00||Networking Coffee Break|
|16:00-17:00||Biotech CEO Panel Series|
A New Value Proposition for Pharma
Changing product and technological developments and a new patient-payer value chain
In recent years, successful science has improved R&D productivity and new technologies have turned life-threatening conditions into manageable chronic diseases. Cost-effective genome sequencing, better clinical data, disruptive technologies such as drones, artificial intelligence, blockchain and measuring actual health outcomes through real-world evidence has elicited the potential of stratified medicines. Against a backdrop of ageing populations and global political shifts, these value chain trends have led to patient-empowered product propositions of value-based schemes that recognise real outcomes, forcing pharma and medtech to readjust and take a leading role in shaping the new healthcare economy.
Jo Pisani Partner Pharmaceuticals & Lifesciences, Strategy& PricewaterhouseCoopers
Meindert Boysen Programme Director Technology Appraisals, National Institute for Health & Care Excellence (NICE)
Chas Bountra Chief Scientist (SGC) & Professor of Translational Medicine, University of Oxford
Melanie Lee Chief Scientific Officer, BTG
Uwe Gottschalk Chief Scientific Officer, Lonza
Disruption from Afar: Embracing New Non-Pharma Technologies & Actors
Is the future of pharma in the hands of drug manufacturing companies?
What role will technology companies such as Google, Apple, Amazon and potentially disruptive technology start-ups play in healthcare? They bring capabilities such as advanced analytics, artificial intelligence, cloud technology and software development that are increasingly appealing to incumbent pharma companies who want to expand their value proposition and play a broader role in healthcare. They have a different view on innovation and return on investment i.e., moving from developing and commercialising medicines to delivering better outcomes by adding patient-centric and technology-enabled services and solutions.
Steve Arlington President, Pistoia Alliance
Ali Parsa Chief Executive Officer, babylon
Andrew Thompson President & Chief Executive Officer, Proteus Digital Health
Patrick Keohane Chief Medical Officer, BenevolentAI
Ray Barlow Chief Executive Officer, e-Therapeutics
Professor Sue Hill OBE Chief Scientific Officer NHS England
The Live, Thrive and Survive Guide to M&A
Are we on the verge of further major pharma industry consolidation?
What is the ideal size and structure of service providers to pharma? Who’s thriving and why? Are collaborations, partnerships between pharma and tech companies (large and small) the way forward as we move towards value-based healthcare models? What is the new commercial model/value proposition for pharma? Outcomes-based / performance-based contracts? On eHealth and mHealth?
Richard Weaver Managing Director, XenoGesis
Vincenzo Di Nicola Managing Director Healthcare Europe, Robert W. Baird & Co
Detlef Behrens Managing Director, Bay Pharma
Tim Luker Director External Innovation, Global External R&D, Eli Lilly and Company
Araz Raoof Head of External Early Drug Development – Europe, Janssen
Financing the Future and Paying for Innovation
How do new commercial models change the innovation investment model?
Will “precision medicine” require a shift to “precision payment”? Does the unpredictability of the current commercial model threaten investment in these areas? Plus, what are the likely changes to the innovation investment model and is it likely to be disrupted? The panel will address these issues and ponder the question: who will the new investors in R&D be and how can venture and early-stage investment influence the current model?
Clive Badman Head of PTS Pre-Competitive Activities, GlaxoSmithKline
Mike Rea, Chief Executive Officer, IDEA Pharma
Hakan Goker Senior Investment Director, Merck Ventures
Catherine Pickering Chief Executive Officer, iOnctura
Jayne Spink Chief Executive Officer, Genetic Alliance UK
Rethinking Pharma Productivity
Changing the way pharma thinks about production, processes and people
As the productivity imperative looms ever-larger, companies need to rethink their strategic options and put productivity at the heart of any upcoming change programme or improvement agenda. Pricing and volume expansion is losing its appeal; advances in technology and analytics are opening the door to new, energetic non-pharma disruptors; and the threat of disintermediation in terms of data and patient engagement has become increasingly significant. Pharma’s R&D and commercial models are under pressure. There’s a problem. But, what’s the solution? Some say that fundamental changes are needed at the human level. Hire better and smarter people and retain them is the new mantra.
Martin Lush Global Vice President, Pharma Biotech and Medical Devices, NSF Health Sciences
Christoph Heinemann Vice President Strategy & Business Management, Global Biologics, Sanofi
Andy Evans Site Lead (Vice President), Macclesfield Multi Format Facility, AstraZeneca
Sean Bermingham Head of Formulated Products, Process Systems Enterprise (PSE)
De-risking Pharma: From Policies and Guidelines to Production
Risk management is a valuable component of an effective quality system
Risk is the probability of occurrence of harm and the severity of that harm. However, achieving a shared understanding of the application of risk management is difficult. In relation to pharmaceuticals, although there are a variety of stakeholders, including patients and medical practitioners as well as government and industry, the protection of the patient by managing the risk to quality should be considered of prime importance. Given that risk and the effective prediction of risk needs intuitive data interpretation, the panel will look beyond the numbers and examine how pharma views, manages and assesses risk.
Martin Lush Global Vice President, Pharma Biotech and Medical Devices, NSF Health Sciences
Andy Tudor Site Quality Operations Lead, Pfizer
Laurent Faboux Senior Vice President, Global Quality Assurance, Ferring Pharmaceuticals
Phill Godden Chief Executive Officer, Protak Scientific
Jenny Yu Senior Underwriter, Special Enterprise Risks, Munich Re
Biotech CEO Panel Series:
Crossing the Valley of Death Between Discovery and Proof of Concept
A dedicated session on how the pharma innovation ecosystem has evolved during the past decade, driven by incubators, both home and abroad, and pre-competitive collaborations between academia, industry, the regulators and the wider supply and value chain companies. But, who’s funding this innovation and at what stage do you license out to Big Pharma? Is it always right that development depends on attracting funds? What is the role of government, healthcare policymakers in nurturing this now critical part of the pharma discovery and development pool?
Howard Marriage Entrepreneur in Residence, Francis Crick Institute
Carl Sterritt Chief Executive Officer, Shield Therapeutics
Ian Tomlinson Chairman, Apollo Therapeutics
Eddy Littler Chief Executive Officer, ReViral
Laurence Barker Chief Business Officer, Dementia Discovery Fund, SV Life Sciences
Iain Thomas Head of Life Sciences Technology Transfer, Cambridge Enterprise
The New Pharma Supply Chain
Data-driven transformation in the pharma industry
Real business impact can be achieved when you apply the right technology to address a functional need. In a post-Theranos environment, healthcare and biotechnology companies are still looking for unicorns in the life science arena, focusing on eHealth, diagnostics and combination therapies. What are the other elements are being considered and what opportunities are really out there?
Jagjit Singh Srai Head, Centre for International Manufacturing, Institute for Manufacturing, University of Cambridge
Andrew Share Director Program Delivery, Advanced Manufacturing Technologies, GlaxoSmithKline
Andrew Fried Life Sciences Europe – Director, IBM
Claes Gustafsson Chief Commercial Officer and Co-Founder ATUM
Outsourcing Strategies: The Evolving Role of CDMOs
Instead of relying on organic market growth alone to propel revenue and profitability, what can CDMOs do differently? Could Big Pharma and CDMOs consider joint ownership or build and operate new business models? And, as globalisation affects the worldwide CDMO market, what are threats and opportunities, and how do CDMOs develop a sustainable business model in this landscape? Smart CDMOs are thinking about the redistribution of capability portfolios as a core strategy and learning from Big Pharma. Is this a viable route to meeting shareholder value? Having well-thought-out strategies that target more attractive segments and capture market share are more crucial than ever for achieving healthy returns and meeting investor expectations!
Jim Hammar International Manufacturing Operations Director, 3M Drug Delivery Systems
David Lowndes Senior Vice President, Head Small Molecule Operating Unit, Shire Pharmaceuticals
Stuart Needleman Chief Commercial Officer, Piramal Pharma Solutions
Lukas Utiger President, Drug Substance, Patheon
The Future of Pharma Biotech
Strategic Alliances and Innovative Outsourcing
The panel will discuss how flexible and innovative outsourcing strategies enable rapid drug development, and how partnerships, strategic alliances and innovative collaborations have driven the biotech industry forward. Topics for debate include project enablement for biotech SMEs, the pros and cons of using multiple expert CROs and CDMOs, and the organisational and operational structures that biotechs should put in place to ensure their success and readiness to compete.
Maureen Coleman Chairman, CN BioInnovations
Tom Mander Chief Operating Officer, Domainex
Mark Bustard Business Development Director, Biologics, The National Biologics Manufacturing Centre, CPI
Bernhard Paul General Manager, European Pharma Solutions, Johnson Matthey
Priya Mande Chief Operating Officer, PsiOxus Therapeutics
The Future of Pharmaceutical Manufacturing and Supply Chains
Disruptive thinking for next-generation pharmaceuticals
A dedicated session on medicines manufacturing innovation, with a focus on disruptive technologies to improve productivity and cater to the future needs of flexibility in manufacturing and the increased demand for personalised diagnostics and medicines. Focus areas will include looking beyond manufacturing to how we can improve the distribution of pharmaceuticals to patients, the ability to supply a patient-specific pack and how both clinical and commercial supply chains are seeking to reduce cycle times and improve right-first-time production.
PK Yegneswaran Vice President Global Technical Operations, Small Molecules, MSD
Dave Tudor Vice President, Head of Strategy, Global Manufacturing and Supply, GlaxoSmithKline
Markus Krumme Head of Continuous Manufacturing, Novartis
Craig Johnston Industry Director, CMAC
Patheon (panelist TBC)
Serialisation: The Clock is Ticking
Regulations, requirements and opportunities
The 2017 deadline for US serialisation has arrived and coded packs are mandatory from November 23rd. In fifteen months’ time, the EU Falsified Medicines Directive (FMD) will also apply from February 2019. Pharmaceutical companies selling prescription medicines in these two biggest regional markets must include both a unique identifier and (in the EU) an anti-tampering device on all their unit-level packaging. Are you ready? What does it all mean for your supply chain and your wider business strategy?
Mark Davison Chief Executive Officer, BlueSphere Health
Andrew Gregory Deputy Director, Head of EU, International and Strategy, Policy Directorate, MHRA
Bart Vansteenkiste Global Sector Manager Life Sciences, Domino Printing Sciences
Aesica Pharmaceuticals, Panellist TBC
Sébastien Mauel Director Serialization & Product Security, Ferring Pharmaceuticals
Delivering the Undeliverable, the Reinvention of CDMOs in an Era of Uncertainty
Demand remains strong but the future marketplace is increasingly diverse and competitive
As the blockbuster era fades into the distant past, pharmaceutical companies — with a keen eye on novel delivery systems, niche indications, HPAPIs, cell/gene therapies and controlled drugs — are casting their nets further and wider in the search for differentiated products. At the same time, a number of major players are targeting more local (close to point of use) manufacturing opportunities. Furthermore, growth in pharmerging economies and stagnation in developed markets, Brexit, Trump reverting to isolationist policies, geopolitical pressure to reshore and a flurry of M&A activity indicates that big players are looking to penetrate new markets and technologies by acquisition.
How will this uncertainty affect service providers such as CDMOs? Should they extend their core competencies into new areas? If so, which do they choose and how to make such a choice? How should contracts be constructed to reflect unnecessary risk? Should they gamble by trying to pick the winners in this turbulent marketplace or sit tight and hope it goes away? Fundamentally, should CDMOs be seriously considering reinventing themselves to remain competitive and cost-effective?
Peter Lyford Business Development Director, Porton Fine Chemicals
Lorenzo Carletti, Vice President Operations Softgel Europe and Asia Pacific, Catalent Pharma Solutions
Anthony Sheehan Chief Executive Officer, Saneca Pharma
Jean-François Hilaire, Executive Vice President Strategy & Global Integration, Recipharm
Pricing, Affordability and an Increased Push for Transparency
How to deliver value to customers
There is a need for increased awareness / knowledge about the value of pharmaceutical innovation to society, but also on the investment / returns proposition of the pharmaceutical business, on the way medicines are priced and the way pharmaceutical companies conduct their business with customers (e.g., transfer of value to customers). Commercial innovation and outcomes-based contracting/managed entry agreements could address the affordability challenge, as well as differential pricing, better/more meaningful data and outcomes collected in development, etc.
Gabrielle Silver Partner, Brunswick Group
Leslie Galloway Chairman, EMIG & Expert Adviser, NICE Centre for Clinical Practice
Ken Jones Chief Executive Officer, Innoture
Nigel Blackburn Director of Drug Development, Centre for Drug Development, Cancer Research UK
Speed to Access: Adaptive and Accelerated R&D
Getting the right medicine to the right patient at the right time
With access challenges even after successful but costly development programmes, industry needs to speed up the clinical development process and produce more for less. What can be done to reduce failure rates when bringing new medicines to market and should we be putting more emphasis on learning from orphan drugs through adaptive licensing and adaptive study designs allowing early but restricted access?
Virginia Acha Executive Director – Research, Medical & Innovation, The Association of the British Pharmaceutical Industry (ABPI)
The Data Debate: Integrity and Access
Privacy, security and ethics
With digitization infiltrating manufacturing and overall healthcare, pharma needs to redefine data analysis, mining, etc., and review data security/privacy. In addition, blockchain, the concept of data integrity throughout the value chain comprising a continuously growing list of ordered records, is fast becoming an industry necessity.
Peter Knight Executive Director, Oxford University Hospitals NHS Trust & Senior Fellow, Nuffield School of Medicine and Population Health, Oxford University
Gerald Law Chief Executive, UK Innovation Forum
Shahid Hanif Head of Health Data & Outcomes, The Association of the British Pharmaceutical Industry (ABPI)
Nick Meade Director of Policy Genetic Alliance UK
Patient Centricity I: Patient Input to Improve Patient Outcomes
Looking at affordability and patient-recorded outcomes, the panel will address the future of immuno-X therapies, therapy experiences and drug interactions, as well as patient-centric dosage forms and medical devices, with a focus on patient centricity driven and enabled by end users: patients and healthcare providers in an R&D partnership. Examining the “Voice of the Patient,” patient representation at the technology assessment stage and validating outcome measures, the panel will discuss how to improve compliance, patient-physician commitment and product-derived value.
Tina Flatau Managing Director, Medannex & OncoBioPharm
Leeza Osipenko Associate Director NICE Scientific Advice, National Institute for Health and Care Excellence
Yury Rozenman Director Business Development and Licensing, Qualcomm Life
Alistair Wickens Chief Executive, roadtohealth
Chris Delaney Chief Executive Officer, Insignia Health
Marco Mohwinckel Vice President Strategy, WebMD Health Corp
Patient Centricity II: The Patient Data Revolution Continues
The panel will table the rise and rise of data inputs in development studies, evidencing value propositions, quality of life assessments and activity monitoring, and examine how companion diagnostics and digital monitoring provide live, virtual data streaming to optimise both clinical decision making, outcomes and healthcare value. Using the example of a diagnostic or monitoring enabled tailored therapy approach, the discussion will address how digital monitoring can help healthcare to move beyond treatment into prevention and sustaining health.
Mark Duman Managing Director and Non-Executive Director, MD Healthcare & Patient Information Forum
Sam Van Alstyne Front End Innovation & New Products Marketing Manager, 3M Drug Delivery Systems
Amer Fasihi Founder, Caros Connect
Lydia Makaroff Director, European Cancer Patient Coalition
Johannes Khinast Scientific Director, Research Centre Pharmaceutical Engineering (RCPE)